Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613001326785
Ethics application status
Approved
Date submitted
11/11/2013
Date registered
2/12/2013
Date last updated
14/05/2015
Type of registration
Retrospectively registered

Titles & IDs
Public title
Identification and characterisation of risk factors for atrial and ventricular arrhythmias in chronic kidney disease (CKD) patients using implantable cardiac monitoring
Scientific title
Identification and characterisation of risk factors for sudden cardiac death in chronic kidney disease patients on regular haemodialysis using an implantable cardiac monitor
Secondary ID [1] 283496 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dialysis 290414 0
Sudden Cardiac Death 290415 0
Chronic Kidney Disease 290548 0
Condition category
Condition code
Cardiovascular 290806 290806 0 0
Other cardiovascular diseases
Renal and Urogenital 290947 290947 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The procedural component of the research will involve insertion of the implantable loop recorder under the skin in the left front chest wall region. This will take approximately 15-20 minutes and is performed under local anaesthetic. The recorder will be implanted for 2 years over which the participant will be monitored on a continuing regular basis.
Intervention code [1] 288203 0
Early detection / Screening
Intervention code [2] 288372 0
Prevention
Comparator / control treatment
A control group for comparison consisting of patients (who may or may not have CKD) with an implantable loop recorder inserted (up to 1 year prior to participation in this study) for routine clinical indications such as lightheadedness or palpitations for investigation will also be followed up.
Control group
Historical

Outcomes
Primary outcome [1] 290802 0
Sudden cardiac death will be determined by a consensus adjudication committee after assessment of electrocardiogram records of the implantable loop recorder, autopsy reports, holter recordings or telemetry tracings and hospital discharge documentation/medical records.
Timepoint [1] 290802 0
Assessed at 12 and 24 months from insertion of implantable loop recorder.
Secondary outcome [1] 305328 0
Significant Arrhythmias will be determined by a consensus adjudication committee after assessment of electrocardiogram records of the implantable loop recorder, holter recordings or telemetry tracings and hospital discharge documentation/medical records.
Timepoint [1] 305328 0
Assessed at 12 and 24 months from insertion of implantable loop recorder.

Eligibility
Key inclusion criteria
1. Any CKD patient on haemodialysis
2. Stable medical therapy for at least one month.
3. All patients must have no prior history of clinical ventricular tachyarrhythmias (including ventricular fibrillation or cardiac arrest) or syncope.
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Pacemaker or Automatic Implantable Cardioverter-Defibrillator in-situ
2. Unstable angina pectoris
3. Uncontrolled hypertension.
4. Known coagulopathy, thrombophilia or contraindications to full systemic anticoagulation
with heparin or warfarin (e.g. haemorrhagic stroke, active bleeding, heparin induced
thrombocytopenic thrombotic syndrome etc.)
5. Inability to provide informed consent
6. Women who are pregnant
7. Children and/or young people (ie. <18 years)
8. Patients experiencing NYHA class IV symptoms and/or LVEF < 35%

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Sample size estimation for this prospective cohort with 95% confidence level and probability of event exposure at
25-30% (approximate 1 in 4 risk of SCD in haemodialysis patients) revealed sample size calculation of this population
proportion to be 50 participants.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
6/08/2012
Actual
6/08/2012
Date of last participant enrolment
Anticipated
Actual
16/12/2013
Date of last data collection
Anticipated
Actual
Sample size
Target
50
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 1642 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment hospital [2] 1643 0
Western Hospital - Footscray
Recruitment postcode(s) [1] 7529 0
3050 - Royal Melbourne Hospital
Recruitment postcode(s) [2] 7530 0
3011 - Footscray

Funding & Sponsors
Funding source category [1] 288200 0
Charities/Societies/Foundations
Name [1] 288200 0
National Heart Foundation
Country [1] 288200 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
St Jude Medical
Address
c2/63-85 Turner St
Port Melbourne VIC 3207
Country
Australia
Secondary sponsor category [1] 286926 0
None
Name [1] 286926 0
Address [1] 286926 0
Country [1] 286926 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 290112 0
Melbourne Health Human Research Ethics Committee
Ethics committee address [1] 290112 0
Ethics committee country [1] 290112 0
Australia
Date submitted for ethics approval [1] 290112 0
Approval date [1] 290112 0
18/07/2012
Ethics approval number [1] 290112 0
2012.055

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 44010 0
Dr Michael Wong
Address 44010 0
Level 2, Department of Cardiology
The Royal Melbourne Hospital,
City Campus, Grattan Street,
Parkville, Victoria,
3050
Country 44010 0
Australia
Phone 44010 0
+613 93427133
Fax 44010 0
Email 44010 0
drmichaelwong@live.com
Contact person for public queries
Name 44011 0
Michael Wong
Address 44011 0
Level 2, Department of Cardiology
The Royal Melbourne Hospital,
City Campus, Grattan Street,
Parkville, Victoria,
3050
Country 44011 0
Australia
Phone 44011 0
+613 93427133
Fax 44011 0
Email 44011 0
drmichaelwong@live.com
Contact person for scientific queries
Name 44012 0
Michael Wong
Address 44012 0
Level 2, Department of Cardiology
The Royal Melbourne Hospital,
City Campus, Grattan Street,
Parkville, Victoria,
3050
Country 44012 0
Australia
Phone 44012 0
+613 93427133
Fax 44012 0
Email 44012 0
drmichaelwong@live.com

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseTemporal distribution of arrhythmic events in chronic kidney disease: Highest incidence in the long interdialytic period.2015https://dx.doi.org/10.1016/j.hrthm.2015.06.033
N.B. These documents automatically identified may not have been verified by the study sponsor.